Systemic corticosteroid treatment in Peyronie's disease
Uzun H. Med Hypotheses. 2013 Dec;81(6):1029-30. doi: 10.1016/j.mehy.2013.09.024. Epub 2013 Sep 27.

Author information

Department of Urology, Recep Tayyip Erdo─čan University, School of Medicine, Rize, Turkey. Electronic address: hakuzun@yahoo.com.

Abstract

Peyronie's disease is characterized by penile pain, plaque or indurated area in the tunica albugenia and penile curvature during erection. Peyronie's disease is a chronic and progressive inflammatory disease. Intralesional corticosteroids have been studied in the treatment of Peyronie's disease due to its inflammatory pathogenesis but hardness of the penile plaque hinders the effective injection and activity of the compound and leads to local side effects. Corticosteroids are the most effective therapy for many inflammatory disorders and systemic use has not been studied in Peyronie's disease. Oral corticosteroids may decrease the pain, improve the penile curvature, reduce the plaque size, and inhibit the formation of fibrosis particularly in the acute inflammatory phase.